Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

BACKGROUND: Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Lei, Kaijian, Jia, Yuming, Ni, Bingqiang, He, Zhiyong, Bi, Minghong, Wang, Xicheng, Shi, Jianhua, Zhou, Ming, Sun, Qian, Wang, Guolei, Chen, Dongji, Shu, Yongqian, Liu, Lianke, Guo, Zhongliang, Liu, Yong, Yang, Junquan, Wang, Ke, Xiao, Ke, Wu, Lin, Yi, Tienan, Sun, Debin, Kang, Mafei, Ma, Tianjiang, Mao, Yimin, Shi, Jinsheng, Tang, Tiegang, Wang, Yan, Xing, Puyuan, Lv, Dongqing, Liao, Wangjun, Luo, Zhiguo, Wang, Bin, Wu, Xiaohong, Zhu, Xiaoli, Han, Shuhua, Guo, Qisen, Liu, Rongyu, Lu, Zhiwei, Zhang, Jianyong, Fang, Jian, Hu, Changlu, Ji, Yinghua, Liu, Guolong, Lu, Hong, Wu, Dedong, Zhang, Junhong, Zhu, Shuyang, Liu, Zheng, Qiu, Wensheng, Ye, Feng, Yu, Yan, Zhao, Yanqiu, Zheng, Qinhong, Chen, Jun, Pan, Zhanyu, Zhang, Yiping, Lian, Wenjuan, Jiang, Bo, Qiu, Bo, Zhang, Guojun, Zhang, Hua, Chen, Yanju, Chen, Yuan, Duan, Hongbing, Li, Manxiang, Liu, Shengming, Ma, Lijun, Pan, Hongming, Yuan, Xia, Yuan, Xueli, Zheng, Yulong, Gao, Emei, Zhao, Li, Wang, Shumin, Wu, Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441057/
https://www.ncbi.nlm.nih.gov/pubmed/34184418
http://dx.doi.org/10.1002/cac2.12179

Ejemplares similares

Ejemplares similares